142217-78-5

Basic information

• Product Name: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol
• Synonyms: (2R,3S,5S)-3-(Benzyloxy)-5-(6-benzyloxy)-2-(4-methyoxyphenyl)diphenylmethylamino)-9H-purin-9-yl)-2-benzyloxymethyl)cyclopentanol;(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol;(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-;(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol ,99%;(1S,2S,3S,5S)-5-(2-((4-Methoxyphenyl)diphenylMethylaMino)-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-((benzyloxy)Methyl)cyclopentanol;[1S-(1α,2β,3α,5β)]-5-[2-[[(4-Methoxyphenyl)-diphenylMethyl]aMino]-6-(phenylMethoxy)-9H- purin-9-yl]-3-(phenylMethoxy)-2-[(phenyl-Methoxy)Methyl]cyclopentanol;Entecavir InterMediate V;Entecavir-5
• CAS NO: 142217-78-5
• Molecular Formula: C₅₂H₄₉N₅O₅
• Molecular Weight: 823.98
• EINECS: 1308068-626-2
• Mol File: 142217-78-5.mol
• Article Data: 3

Chemical Properties

• Appearance: Colorless transparent liquid
• Density: 1.23
• Refractive Index: 1.645
• Storage Temp.: 2-8°C
• Solubility: Acetonitrile (Slightly, Sonicated), DMSO (Slightly, Sonicated), Methanol (Slight
• PKA: 13.87±0.70(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol(142217-78-5)
• EPA Substance Registry System: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol(142217-78-5)

Safety Data

• Hazardous Substances Data: 142217-78-5(Hazardous Substances Data)

Usage

Uses

Entecavir-?5 is used in the preparation of the anti-?HBV drug Entecavir.

InChI:InChI=1/C52H49N5O5/c1-59-43-29-27-42(28-30-43)52(40-23-13-5-14-24-40,41-25-15-6-16-26-41)56-51-54-49-47(50(55-51)62-34-39-21-11-4-12-22-39)53-36-57(49)45-31-46(61-33-38-19-9-3-10-20-38)44(48(45)58)35-60-32-37-17-7-2-8-18-37/h2-30,36,44-46,48,58H,31-35H2,1H3,(H,54,55,56)/t44-,45-,46-,48?/m0/s1

Upstream product

• 142217-77-4 [1S-(1α,2β,3α,5β)]-5-(2-amino-6-benzyloxy-9H-purin-9-yl)-3-benzyloxy-2-(benzyloxy)methyl-cyclopentanol 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 3587-60-8 Benzyloxymethyl chloride 
• 39939-07-6 5-(benzyloxymethyl)cyclopentadiene 
• 110567-22-1 (2R,3S)-benzyloxy-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexane 
• 117641-39-1 (2R,3S)-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexan-3-ol 
• 110567-21-0 (1S,2R)-2-(benzyloxymethyl)-1-hydroxy-3-cyclopentene 
• 4984-82-1 sodium cyclopentadienylide 

Downstream Products

• 142217-79-6 (2R,3S,5S)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-benzyloxy-9H-fluoren-9-yl]-3-benzyloxy-2-[(benzyloxy)methyl]cyclopentanone 
• 142217-80-9 6-(benzyloxy)-9-((1S,3R,4S)-4-(benzyloxy)-3-((benzyloxy)methyl)-2-methylidenecyclopentyl)-N-((4-methoxyphenyl)diphenylmethyl)-9H-purin-2-amine 
• 142217-69-4 entecavir 
• 142217-81-0 2-amino-1,9-dihydro-9-[(1S,3R,4S)-2-methylene-4-(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclopentyl]-6H-purin-6-one 
• 131043-40-8 2-amino-1,9-dihydro-9-<<1S-(1α,2α,3α,4β)>-2-fluoro-4-hydroxy-3-(hydroxymethyl)cyclopentyl>-6H-purin-6-one 

Relevant articles and documents

Improved entecavir intermediate synthesis process and improved entecavir synthesis process

The invention discloses an improved entecavir intermediate synthesis process and an improved entecavir synthesis process, and relates to the technical field of drug synthesis. The invention disclosesan improved entecavir intermediate synthesis process. In the synthesis process of an amino protection reaction product, amino protecting groups are added in batches; and the ratio of the reaction rawmaterials is optimized, so that the problems of long reaction time and relatively low amino protection reaction yield due to adoption of a one-time complete feeding mode in an existing synthesis modeare solved, the synthesis time of an amino protection reaction product is shortened to 50-70 minutes, and the obtained product is high in yield and purity. According to the improved entecavir synthesis process, in the amino protection reaction product synthesis process, reaction conditions are effectively optimized, and the purity of obtained entecavir reaches 99% or above.

Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines

Antiviral activity is exhibited by compounds having the formula STR1 and its pharmaceutically acceptable salts.